Category: Medical
-
STAT+: Trump and RFK Jr. are mulling their most disruptive vaccine policies yet — alarming manufacturers
•
WASHINGTON — As the Trump administration moves ahead on what could be its most wide-reaching vaccine changes yet,…
-
STAT+: Many poor countries where experimental drugs are tested fail to benefit after approval, analysis finds
•
Numerous medicines are not accessible in many of the countries where they were tested before approval by the…
-
STAT+: Johnson & Johnson acquires Halda Therapeutics for $3 billion, a big win for a buzzy new technology
•
Johnson & Johnson said Monday it will purchase Halda Therapeutics and its experimental prostate cancer drugs for $3.05…
-
STAT+: European firms raise two big funds for early biotech
•
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
-
STAT+: Pharmalittle: We’re reading about Novo plans for Wegovy, a Purdue bankruptcy deal, and more
•
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating,…
-
STAT+: China’s WuXi AppTec, after evading threat of U.S. restrictions, comes out ahead
•
For nearly two years, WuXi AppTec, the Chinese contract research giant with extensive ties with U.S. biotech and…
-
Opinion: STAT+: Sanofi CEO: How we’re measuring AI success
•
With tech powerhouses forming billion dollar alliances — from NVIDIA and OpenAI to AMD and IBM’s partnership with…
-
STAT+: Pfizer closes $10 billion Metsera deal
•
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
-
Judge says he’ll approve opioid settlement with OxyContin maker Purdue and Sackler family
•
NEW YORK — A federal bankruptcy court judge on Friday said he will approve OxyContin-maker Purdue Pharma’s latest…
-
STAT+: Up and down the ladder: The latest comings and goings
•
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with…
-
STAT+: Pharmalittle: We’re reading about a Merck acquisition, Novo facing shareholder backlash, and more
•
And so, another working week will soon draw to a close. Not a moment too soon, yes? This…
-
STAT+: Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial
•
A closely watched next-generation blood thinner being developed by Bristol Myers Squibb and Johnson & Johnson failed in…
-
STAT+: Merck to buy Cidara, maker of a flu prevention drug, for $9.2B
•
Merck said Friday it would buy Cidara Therapeutics, the maker of an experimental flu therapy, in a $9.2…
-
Opinion: The era of safe bets in psychiatric medicine is over
•
For decades, the pharmaceutical industry’s approach to mental health was a playbook of conservative, incremental innovation. The market…
-
STAT+: Makary, Prasad outline pathway for bespoke gene therapy
•
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
-
STAT+: Pfizer signals brewing digital health work
•
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the…
Recent Posts
- Sources: Sesko set for United return in December
- Nigeria: Policy Alert Pushes for Women Inclusiveness in Hcdts in Rivers
- Harriette Cole: It stung to hear what my mom said the day before she died
- Transfer rumors, news: Man City, Liverpool, Spurs eye Semenyo release clause
- Nigeria: Kano Senator Ties Knot With Military Officer in Low-Key Ceremony
- Nigeria: Osun 2026 – INEC Urges Political Parties to Conduct Lawful Primaries
- Miss Manners: She posted online that I stole her socks. What do I do now?
- STAT+: Trump and RFK Jr. are mulling their most disruptive vaccine policies yet — alarming manufacturers
- How serious is Labour backlash over asylum plans?
- Nestle accused of risking baby heath in Africa, Asia and Latin America
- Female ref alleges coach pushed and harassed her
- Ryan Reynolds’ other club finished rock bottom
Social Media
Advertisement
